Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

This recognition follows another recent honor for Mr. Kras, who was named a finalist for the Entrepreneur Of The Year® 2024 New Jersey Award by Ernst & Young (EY US). This award celebrates innovative ...

Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...

A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...

A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations. The news was announced in a stock exchange filing ...

Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

The drug is designed to inhibit several oncogenic KRAS mutations, which are prevalent in various human cancers. Mitchell Shirvan, Ph.D., Chief Scientific Officer of Silexion, expressed enthusiasm ...

Belvidere-based Edible Garden is bringing something new to the table. After a successful pilot production, the hydroponic ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...